Trial record 8 of 115 for:    Polycystic Kidney Disease

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02160145
Recruitment Status : Completed
First Posted : June 10, 2014
Last Update Posted : October 17, 2017
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 14, 2017
  Actual Study Completion Date : April 14, 2017
  Certification/Extension First Submitted : September 18, 2017